Hang Seng Index Rebounds After Early Losses as Tech Stocks Rally
AM730 · 2 SOURCESabout 2 hours ago2 MIN
Summary
The Hang Seng Index opened 62 points lower at 24,282 on Wednesday, October 14, 2026, before staging a recovery that pushed the benchmark as high as 24,524, a gain of 179 points intraday. The index ultimately closed 31 points or 0.13 percent lower at 24,314, with market turnover exceeding 193.4 billion Hong Kong dollars. The reversal came despite New York Federal Reserve Bank President John Williams reiterating the Fed's commitment to one additional interest rate hike this year to combat inflation, which had dragged US equity markets lower overnight .
Key Points
- The Hang Seng Index opened at 24,282 points, dipped intraday, then rallied to a high of 24,524 before closing at 24,314, down 31 points
- John Williams of the New York Federal Reserve indicated the Fed will raise rates once more in 2026 to curb inflation, pressuring overnight US markets
- Meituan (stock code: 3690) surged 6.6 percent to become the best-performing blue chip; Alibaba (stock code: 9988) rose 3 percent and Xiaomi (stock code: 1810) gained 5.3 percent
- The Tech Index closed 37 points higher at 4,174, up 0.91 percent, reversing from an early loss of less than 1 point
- Akeso Biopharma (Kangfang Shengwu) plummeted 9.6 percent after announcing a placement at nearly 7 percent discount, dragging other biotech stocks lower
Why It Matters
The intraday recovery demonstrates Hong Kong market resilience despite external pressures from potential Fed rate increases, with investors rotating into tech names that have shown strong earnings potential . The weakness in biotech stocks, particularly following Akeso Biopharma's deeply discounted placement, signals caution about valuations in the healthcare sector and may indicate broader concerns about capital-raising conditions in the market .
The intraday recovery demonstrates Hong Kong market resilience despite external pressures from potential Fed rate increases, with investors rotating into tech names that have shown strong earnings potential . The weakness in biotech stocks, particularly following Akeso Biopharma's deeply discounted placement, signals caution about valuations in the healthcare sector and may indicate broader concerns about capital-raising conditions in the market .